文献速递咽喉与嗓音

靶向Engrailed-1成纤维细胞治疗特发性声门下狭窄

Targeting Engrailed‐1 Fibroblasts in Idiopathic Subglottic Stenosis
RSS 订阅 · The Laryngoscope · 2026-10-28

该研究分析6例iSGS患者病变声门下与远端健康气管,发现病变组织EN1表达升高(倍数58.86,SD=65.12,p=0.031);体外用verteporfin(5 μM)处理iSGS成纤维细胞可降低COL1A1、COL3A1、EN1及YAP/TAZ通路基因表达。

要点

  • iSGS病变声门下EN1表达显著升高。
  • verteporfin抑制iSGS成纤维细胞纤维化基因表达。
  • 靶向EN1成纤维细胞或为iSGS抗纤维化策略。

核心结论

  • EN1及YAP/TAZ信号通路在iSGS中表达增加,verteporfin体外可抑制YAP/TAZ并降低EN1和COL1A1表达。

研究设计与样本

  • 比较6例iSGS患者病变声门下与远端健康气管组织,并用verteporfin(5 μM)处理iSGS来源成纤维细胞进行体外基因和蛋白表达分析。

主要发现

  • iSGS声门下EN1表达较对照升高(倍数58.86,SD=65.12,p=0.031)。
  • verteporfin使iSGS成纤维细胞COL1A1基因表达降低81.75%(SD=9.28,p=0.031)。
  • verteporfin使COL3A1基因表达降低22.77%(SD=17.11,p=0.031)。
  • verteporfin使EN1表达降低26.32%(SD=28.25,p=0.031),并降低AMOTL2、CCN1、CCN2、YAP1、WWTR1等YAP/TAZ相关基因。

临床怎么用

  • verteporfin体外可减少iSGS成纤维细胞纤维化基因表达,提示靶向EN1/YAP/TAZ通路可能成为iSGS治疗方向。

局限性

  • 证据级别为N/A,样本量小(n=6),verteporfin效果仅为体外实验,尚需进一步临床前和临床验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

This study demonstrates increased expression of Engrailed-1 (EN1) and YAP/TAZ pathway related genes in fibrotic tissue from patients with idiopathic subglottic stenosis (iSGS). Treatment of iSGS-derived fibroblasts with the YAP/TAZ inhibitor verteporfin, reduced profibrotic gene and collagen expression, suggesting a potential therapeutic approach for this disease. ABSTRACT Objective Idiopathic subglottic stenosis (iSGS) is characterized by pathologic deposition of extracellular matrix (ECM) secondary to dysregulated fibroblasts. Engrailed-1 expressing fibroblasts have been shown to promote ECM deposition in fibrosis. Verteporfin has been shown to reduce EN1 expression in fibroblasts through YAP/TAZ signaling. However, EN1 expression, YAP/TAZ signaling, and verteporfin treatment have not been investigated in iSGS pathogenesis. Methods Biopsies of diseased subglottis and distal healthy trachea of iSGS patients (n = 6) were assessed. qRT-PCR, analysis of iSGS single-cell RNA sequencing data, flow cytometry and immunochemistry were used to compare the expression of EN1. Fibroblasts from diseased iSGS tissue were treated with verteporfin (5 μM) or control and gene and protein expression analysis was performed for EN1, YAP/TAZ pathway and fibrotic genes. Results The iSGS subglottis demonstrated increased expression of EN1 (fold change = 58.86, SD = 65.12, p: 0.031) compared to controls. Immunohistochemistry analysis of the diseased iSGS subglottis showed that EN1 was densely expressed. Verteporfin treatment of iSGS fibroblasts in vitro led to an 81.75% (SD = 9.28, p: 0.031) reduction in COL1A1 and 22.77% (SD = 17.11, p: 0.031) reduction in COL3A1 gene expression. This was associated with a 26.32% (SD = 28.25, p: 0.031) reduction in EN1 expression and reductions in the YAP/TAZ associated genes AMOTL2, CCN1, CCN2, YAP1, and WWTR1. Conclusion EN1 and the associated YAP/TAZ signaling pathway are increased in iSGS. Verteporfin treatment inhibited YAP/TAZ expression and attenuated EN1 and COL1A1 expression in vitro. Targeting EN1 expressing fibroblasts through inhibition of YAP/TAZ signaling represents a potential therapeutic target to reduce fibrosis in iSGS. Level of Evidence N/A.

来源:The Laryngoscope,查看原文。版权归原作者所有。

引用

  1. The Laryngoscope:Targeting Engrailed‐1 Fibroblasts in Idiopathic Subglottic Stenosis

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。